Zobrazeno 1 - 10
of 88 698
pro vyhledávání: ''
Autor:
Lorinda Simms, Shehkar Patil, David R. Gandara, Anders Mellemgaard, Raghunadharao Digumarti, Bonne Biesma, Johan Vansteenkiste, Mauro Zukin, Joachim von Pawel, Katherine P. Sugarman, Keunchil Park, Christian Manegold, Filippo de Marinis, Tuncay Göksel, Janusz Rolski, Piotr Serwatowski, Jin S. Lee, Giorgio V. Scagliotti, Ulrich Gatzemeier, Purvish M. Parikh
Publikováno v:
Journal of Clinical Oncology. 41:2458-2466
PURPOSE Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS
Autor:
David H. Johnson, Roy S. Herbst, Corey J. Langer, Louis Fehrenbacher, William Novotny, Eric Holmgren, Jacques Gaudreault, John Nemunaitis, David M. Jablons, Fairooz F. Kabbinavar, Russell F. DeVore, Lisa A. Damico
Publikováno v:
Journal of Clinical Oncology. 41:2305-2312
Purpose To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. Patients and Methods In a phase II trial, 99 patients were randomly assigned to bevacizum
Autor:
Ulrich Gatzemeier, Michael Boyer, Paolo Paoletti, Salih Emri, Christian Manegold, Claude Denham, Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski, Clet Niyikiza, E. Kaukel, Pierre Ruffié
Publikováno v:
Journal of Clinical Oncology. 41:2125-2133
PURPOSE Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy. We conducted a phase III trial to determine whether treatment with
Autor:
Virginia Paton, Gracie Lieberman, Melody A. Cobleigh, Debasish Tripathy, Nicholas J. Robert, Charles L. Vogel, Louis Fehrenbacher, Janet M. Wolter, Steven Shak, Susy Scholl, Dennis J. Slamon
Publikováno v:
Journal of Clinical Oncology. 41:1501-1510
PURPOSE Overexpression of the HER2 protein occurs in 25% to 30% of human breast cancers and leads to a particularly aggressive form of the disease. Efficacy and safety of recombinant humanized anti-HER2 monoclonal antibody as a single agent was evalu
Publikováno v:
Journal of the Royal Society of Medicine. 113(11)
Tamoxifen exposure is a recognised risk for primary endometrial cancer. This case serves as a reminder to meticulously check the past medical history and inform patients of the risk-benefit of treatment as part of a shared-decision making process.
Autor:
Foteinos-Ioannis Dimitrakopoulos, Kyriaki Papadopoulou, Dimitrios Pectasides, Anna Batistatou, Kitty Pavlakis, George Fountzilas, Helen P. Kourea, Sofia Chrisafi, George Pentheroudakis, Vassiliki Kotoula, Pavlos Papakostas, Eleni Galani, Eleni Res, Dimitrios Bafaloukos, Angelos Koutras, Georgia-Angeliki Koliou, Mattheos Bobos, Kyriakos Chatzopoulos, Anthoula Asimaki-Vlachopoulou
Publikováno v:
Cancer Research and Treatment. 54:1053-1064
Purpose Angiogenesis is a crucial phenomenon in the development and progression of breast cancer (BC), but the clinical significance of angiogenesis-related proteins in metastatic BC remains unknown. This study investigates the prognostic value of va
Autor:
Chim C. Lang, Jasper Tromp, R. A. de Boer, Peter van der Meer, Kenneth Dickstein, Adriaan A. Voors, Marco Metra, George Markousis-Mavrogenis, Dirk J. van Veldhuisen, Wouter Ouwerkerk, S.D. Anker, Joao Pedro Fereirra, Nilesh J. Samani, John G.F. Cleland, Gerasimos Filippatos
Publikováno v:
Cardiovascular Research (CVR)
Cardiovascular Research, 118(8), 1964-1977. Oxford University Press
Cardiovascular research, 118(8), 1964-1977. Oxford University Press
Cardiovascular Research, 118(8), 1964-1977. Oxford University Press
Cardiovascular research, 118(8), 1964-1977. Oxford University Press
Aims The exploration of novel immunomodulatory interventions to improve outcome in heart failure (HF) is hampered by the complexity/redundancies of inflammatory pathways, which remain poorly understood. We thus aimed to investigate the associations b
Publikováno v:
Cancer Research and Treatment. 54:469-477
Purpose In hormone receptor-positive, human epidermal growth factor receptor 2–negative metastatic breast cancer (HR+ HER2–MBC), the mainstay treatment options include cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and everolimus (EVE) in combi
Autor:
Sophie Tartas, Mei Chen, Hans J. Hammers, Barbara Haber, Thomas Powles, Raymond S. McDermott, Michael B. Atkins, Chihiro Kondoh, Cynthia G. Silber, Lori Wood, Elizabeth R. Plimack, Yaroslav Shparyk, Przemyslaw Langiewicz, Boris Alekseev, Denis Soulières, Jens Bedke, Erin Jensen, Bohuslav Melichar, Brian I. Rini
Publikováno v:
European Urology Oncology. 5:225-234
Pembrolizumab plus axitinib improved efficacy over sunitinib in treatment-naive advanced renal cell carcinoma in the KEYNOTE-426 (NCT02853331) study. However, a relatively high incidence of grade 3/4 aminotransferase elevations was observed.To furthe
Publikováno v:
Clinical Breast Cancer. 22:e310-e318
Background Anthracycline and taxane-based doublets have largely replaced cyclophosphamide, methotrexate, and fluorouracil (CMF) as preferred regimens in the adjuvant treatment of breast cancer. Metronomic CMF is associated with improved tolerability